Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox

Arnaud Bayle; Antoine Italiano; Christophe Massard; Jean Yves Blay; Aurelien Marabelle

doi:10.1016/j.ejca.2021.12.008

Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox

Arnaud Bayle, Antoine Italiano, Christophe Massard, Jean Yves Blay, Aurelien Marabelle

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	128-129
Nombre de pages	2
journal	European Journal of Cancer
Volume	162
Les DOIs	https://doi.org/10.1016/j.ejca.2021.12.008
état	Publié - 1 févr. 2022

Accès au document

10.1016/j.ejca.2021.12.008

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{656e692b89484e00bae386647564317e,

title = "Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox",

author = "Arnaud Bayle and Antoine Italiano and Christophe Massard and Blay, {Jean Yves} and Aurelien Marabelle",

note = "Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AB: as part of the Drug Development Department (DITEP), principal/sub-investigator of clinical trials for AbbVie, Adaptimmune, Adlai Nortye USA Inc, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, BBB Technologies Bv, Beigene, BicycleTx Ltd, Bioalliance Pharma, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Cullinan-Apollo, CureVarc, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Therapeutics, Gamamabs, Genentech, GlaxoSmithKline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, MedImmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merus, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre Medicament, Plexxikon, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Turning Point Therapeutics, Xencor. Research Grants from Astra Zeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. Non-financial support (drug supplied) from Astra Zeneca, Bayer, BMS, Boringher Ingelheim, GSK, MedImmune, Merck, NH TherAGuiX, Pfizer, Roche. AI: advisory board (Bayer, Chugai, Daiichy Sankyo Foundation Medicine, GSK, Roche, Springworks), research grants (Astra Zeneca, Bayer, Chugai, Merck, MSD, Roche) CM: consultant/advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion. JYB: research support and honoraria from Roche, Bayer, Deciphera, MSD, BMS, GSK. AM was an investigator in the KN-158 trial (NCT02628067) which provided the rationale for the FDA approval of pembrolizumab in MSI-high and TMB-high tumours and the coordinator of the Acse nivolumab trial (NCT03012581) which contained a cohort of patients with non-CRC MSI-high tumours. AM is the principal investigator of the PEMBIB trial (NCT02856425) where MSD provided free pembrolizumab to Gustave Roussy. Over the last 5 years, AM participated in one scientific advisory board for MSD on a molecule different from pembrolizumab. AM is the principal investigator of a Gustave Roussy pre-clinical project funded by the Foundation MSD Avenir on the immune atlas of cancers.",

year = "2022",

month = feb,

day = "1",

doi = "10.1016/j.ejca.2021.12.008",

language = "English",

volume = "162",

pages = "128--129",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

TY - JOUR

T1 - Basket trial health technology assessment requirements and limited access to innovations in oncology

T2 - The French paradox

AU - Bayle, Arnaud

AU - Italiano, Antoine

AU - Massard, Christophe

AU - Blay, Jean Yves

AU - Marabelle, Aurelien

N1 - Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AB: as part of the Drug Development Department (DITEP), principal/sub-investigator of clinical trials for AbbVie, Adaptimmune, Adlai Nortye USA Inc, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, BBB Technologies Bv, Beigene, BicycleTx Ltd, Bioalliance Pharma, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Cullinan-Apollo, CureVarc, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Therapeutics, Gamamabs, Genentech, GlaxoSmithKline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, MedImmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merus, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre Medicament, Plexxikon, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Turning Point Therapeutics, Xencor. Research Grants from Astra Zeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. Non-financial support (drug supplied) from Astra Zeneca, Bayer, BMS, Boringher Ingelheim, GSK, MedImmune, Merck, NH TherAGuiX, Pfizer, Roche. AI: advisory board (Bayer, Chugai, Daiichy Sankyo Foundation Medicine, GSK, Roche, Springworks), research grants (Astra Zeneca, Bayer, Chugai, Merck, MSD, Roche) CM: consultant/advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, Orion. JYB: research support and honoraria from Roche, Bayer, Deciphera, MSD, BMS, GSK. AM was an investigator in the KN-158 trial (NCT02628067) which provided the rationale for the FDA approval of pembrolizumab in MSI-high and TMB-high tumours and the coordinator of the Acse nivolumab trial (NCT03012581) which contained a cohort of patients with non-CRC MSI-high tumours. AM is the principal investigator of the PEMBIB trial (NCT02856425) where MSD provided free pembrolizumab to Gustave Roussy. Over the last 5 years, AM participated in one scientific advisory board for MSD on a molecule different from pembrolizumab. AM is the principal investigator of a Gustave Roussy pre-clinical project funded by the Foundation MSD Avenir on the immune atlas of cancers.

PY - 2022/2/1

Y1 - 2022/2/1

UR - http://www.scopus.com/inward/record.url?scp=85121999861&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2021.12.008

DO - 10.1016/j.ejca.2021.12.008

M3 - Letter

C2 - 34983014

AN - SCOPUS:85121999861

SN - 0959-8049

VL - 162

SP - 128

EP - 129

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -